Company intelligence / Profile preview
BIAL
Trofa, Porto, Portugalbial.com ↗
- Ownership
- Private
- Employees
- ~935
- Development stage
- Other
01
Overview
BIAL has successfully developed and commercialized two drugs, Zebinix and Ongentys, which represent 55% of their turnover. Their lead asset BIA 28-6156 (formerly LTI-291) has completed Phase 1 trials and is currently in Phase 2 clinical trials for GBA1 Parkinson's disease. The ACTIVATE Phase 2 study had its first patient complete the full dose regimen in January 2025[10].
- Therapeutic areas
- Rare DiseasesCardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Sumitomo Pharma (10-year licensing agreement for Parkinson's medicine in Europe)
Beyond the preview
Go deeper on BIAL.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIAL.